JW Pharmaceutical announced on the 12th that it will participate in the global phase 4 clinical trial for the hair care cosmetic product ‘Ducray Neoptide Expert’ from French global pharmaceutical company Pierre Fabre.
Ducray Neoptide Expert is a hair care cosmetic from Pierre Fabre of France. JW Shinyak signed an exclusive domestic supply contract with Pierre Fabre and began full-scale domestic sales in January of this year.
The global phase 4 clinical trial is a clinical trial that will be conducted for 6 months from September to March next year to follow up on the efficacy and improve safety of ‘Ducray Neoptide Expert’. It is scheduled to be conducted simultaneously in 15 countries around the world, including Europe, Asia, the Middle East, South America, and Africa, and in Korea, JW Shinyak will be in charge of this phase 4 clinical trial.
The Korean clinical trial led by JW Shinyak will be participated by three institutions: the Korean Society of Hair Restoration, the Korean Society of Hair Restoration, and the Korean Society of Dermatologists. They plan to conduct research on a total of approximately 200 subjects who require follow-up care for the scalp and hair after hair loss treatment at five major university hospitals and 15 specialized clinics in Korea.
A JW Pharmaceutical official said, “This global phase 4 clinical trial is an opportunity to prove the excellent hair care effects of ‘Ducray Neoptide Expert’ worldwide,” and added, “We will continue to make efforts in various ways so that hair care cosmetics can establish themselves as a solid choice for consumers and patients who are concerned about hair care.”
Source: kormedi.com
